BIO to cut ties with WuXi af­ter trade group was ac­cused of act­ing as a for­eign agent

The biotech in­dus­try’s ma­jor lob­by­ing group in Wash­ing­ton will end its as­so­ci­a­tion with the Chi­nese ser­vices com­pa­ny WuXi AppTec, which has been tar­get­ed by mem­bers of Con­gress as a US na­tion­al se­cu­ri­ty risk.

In a press re­lease Wednes­day af­ter­noon, the Biotech­nol­o­gy In­no­va­tion Or­ga­ni­za­tion said it will take steps to “sep­a­rate from WuXi-AppTec re­gard­ing mem­ber­ship” and sup­port the BIOSE­CURE Act. That leg­is­la­tion would po­ten­tial­ly ban WuXi and sev­er­al oth­er Chi­nese health­care firms from do­ing work in the US or with US com­pa­nies.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.